Related Experiment Video
Updated: Jan 13, 2026

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
Published on: January 7, 2018
1,1-Diethoxyethane increases insulin sensitivity and ameliorates obesity and dyslipidemia in mice fed high-fat diet
Thang Nguyen Huu1, Hien Duong Thanh2, Min-Kyu Kim3
1Department of Biochemistry, Department of Biomedical Sciences, Research Center for Aging and Geriatrics, Research Institute of Medical Sciences, Chonnam National University Medical School, Gwangju, Republic of Korea.
Abstract:
Alcoholic beverages have been concerned not only for gastronomic delight but also for certain impacts on health, such as obesity, diabetes, and cardiovascular diseases. In this study, we assessed the bioactive functions of 1,1-Diethoxyethane (1,1-DEE), a flavoring compound formed during the aging process of wine by flor yeast, using both cultured cell lines and a high-fat diet (HFD) mouse model. 1,1-DEE was identified in the batches of ethanol that induced oxidation of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) using gel mobility shift assay and gas chromatography-mass spectrometry. PTEN was reversibly oxidized when exposed to 1,1-DEE, but 1,2-DEE did not induce PTEN oxidation. Mechanistically, 1,1-DEE treatment enhanced the production of mitochondrial reactive oxygen species, accompanying by oxidation of PTEN and subsequent activation of Akt signaling. 1,1-DEE treatment elevated Akt activation when combined with insulin, compared with insulin alone, and alleviated palmitate-induced insulin resistance in C2C12 myoblasts. Moreover, the oral administration of 1,1-DEE alleviated glucose intolerance and insulin resistance in HFD-fed mice. 1,1-DEE also mitigated HFD-induced body weight gain and hepatic dyslipidemia without reduction of food intake. Transcriptome analysis revealed significant genes involved in the improvement of insulin sensitivity and dyslipidemia. Thus, 1,1-DEE may serve as a promising therapeutic agent for the intervention of obesity, diabetes, and dyslipidemia.
Related Concept Videos
Oral Hypoglycemic Agents: Biguanides and Glitazones
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

